[EirGenix] Licensing Partner Sandoz Submits Variation Application to EMA for EG12014 to Add 420mg Vial Dosage
NQ Score
0/100
N1 Content Completeness
5
AI Summary (NQ-processed)
EirGenix announced that its partner Sandoz has submitted a Type II variation application to the EMA for trastuzumab biosimilar EG12014 to add a 420mg vial in addition to the already approved 150mg vial.